CLINICAL_TRIALS
trial_result
· 2020-07-08
Clinical Trial Update: Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA [Phase 3]
Summary
Phase 3 trial evaluating pitolisant (BF2.649) for excessive daytime sleepiness in obstructive sleep apnea has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bioprojet | Conditions: Excessive Daytime Sleepiness, Obstructive Sleep Apnea | Phase 3 | Status: COMPLETED